New drug combo shows promise for rare sarcoma

NCT ID NCT05301764

Completed Disease control Sponsor: Lyvgen Biopharma Holdings Limited Source: ClinicalTrials.gov ↗

First seen May 22, 2026 · Last updated May 22, 2026 · Updated 1 time

Summary

This study tested a new drug (LVGN6051) combined with an existing drug (anlotinib) in 39 adults with advanced soft tissue sarcoma that had not responded to other treatments. The main goals were to check safety and find the best dose, and to see if the combination could shrink tumors. The trial has been completed, but results are not yet reported.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China
Henan cancer hospital

Zhenzhou, Henan, 450008, China
Hunan Cancer Hospital

Changsha, Hunan, 410031, China
Shanghai Sixth People's Hospital

Shanghai, Shanghai Municipality, 200233, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China

Conditions

Explore the condition pages connected to this study.

SOFT TISSUE SARCOMA